clinical trial · NCT05011851
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Angelman SyndromeNNZ-2591
brief summary
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome
started
Jul 12, 2022
primary completion
May 13, 2024
completion
Jul 16, 2024
last updated
Jan 31, 2025
detailed description
The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution, 50mg/L, in children and adolescents with Angelman syndrome. The secondary purpose is to investigate measures of efficacy of subjects will receive treatment of 50mg/mL orally administered NNZ-2591 for a total of 13 weeks
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol